Machine Learning

Indian tech firm Lexlegis launches its Legal AID platform in the U.S., promising a new 'Legal Intelligence Factory' free from AI errors.

Independent firm FPA is nominated for a top Morningstar award alongside PIMCO and Vanguard, highlighting its rare focus on investor returns over asset size.

FDA greenlights a novel, AI-discovered therapy for a Phase 1 trial, offering new hope for children with devastating central nervous system tumors.

A new clinical study compares a powered prosthetic knee against current tech, promising to reduce effort and revolutionize mobility for amputees.

A gene expression test is changing melanoma care by providing risk data beyond traditional staging, enabling more tailored treatment for patients.

Hyundai, Genesis, and Kia secured 16 top safety ratings, including 15 TSP+ awards, showcasing their leadership under the IIHS's toughest criteria yet.

LM Funding reports higher revenue and record Bitcoin mining but a staggering $17.9M Q4 loss reveals the harsh reality of crypto market swings.

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.

The University of Maryland secured $1M in federal funds to help small businesses adopt AI, aiming to boost efficiency and level the economic playing field.

With a fresh Nasdaq listing and $57.2M in funding, Satellos is advancing a novel muscle-regenerating drug for Duchenne into pivotal pediatric trials.

A major investment aims to develop biomarkers for TAND, the neuropsychiatric challenges affecting most with TSC, offering new hope for families.

At its Hong Kong summit, Noah Holdings revealed a new playbook for global investors, leveraging AI to build resilient wealth structures in a changing world.

The Chinese entertainment giant posted staggering profit growth, fueled by box office hits, a live event boom, and a savvy, tech-driven strategy.

Neutech Group builds on its education, healthcare, and wellness strategy, but a closer look at its 2025 financials reveals a more complex picture.

A French biopharma's leap in synthetic lipid production de-risks its lead drug, eyes a vast sepsis market, and creates new commercial avenues.

The pharma giant's acquisition of Excellergy and its first-in-class Exl-111 could revolutionize treatment for millions with severe, debilitating allergies.

Agenus prepares a crucial update on its BOT+BAL immunotherapy, a potential breakthrough for cancers resistant to current treatments. What will they reveal?

EnerSys will unveil its strategic framework and technology roadmap, outlining its plan to navigate the energy transition and capitalize on market growth.

Heritage Global promotes 20-year veteran Tom Ludwig to President of NLEX, signaling a focus on compliance and stability in the volatile loan sale market.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.